

Ian Anthony Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1599319/publications.pdf>

Version: 2024-02-01

223
papers

32,150
citations

16451

64
h-index

5255

165
g-index

227
all docs

227
docs citations

227
times ranked

44847
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal risk of death, hospitalizations for atrial fibrillation, and cardiovascular events following catheter ablation of atrial fibrillation: a cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 150-160.	4.0	2
2	Maternal and Childhood Ambient Air Pollution Exposure and Mental Health Symptoms and Psychomotor Development in Children: An Australian Population-Based Longitudinal Study. <i>Environment International</i> , 2022, 158, 107003.	10.0	19
3	USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening) Tj ETQq1 1 0,784314 rgBT /O 10.7 66	10.7	66
4	Ambient air pollution and acute respiratory infection in children aged under 5 years living in 35 developing countries. <i>Environment International</i> , 2022, 159, 107019.	10.0	24
5	Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. <i>Lancet Respiratory Medicine</i> , 2022, 10, 497-511.	10.7	121
6	Residential greenspace and early childhood development and academic performance: A longitudinal analysis of Australian children aged 4–12 years. <i>Science of the Total Environment</i> , 2022, 833, 155214.	8.0	7
7	Development of an Electronic Interdisciplinary Chronic Obstructive Pulmonary Disease (COPD) Proforma (E-ICP) to Improve Interdisciplinary Guideline Adherence in the Emergency Department: Modified Delphi Study. <i>International Journal of COPD</i> , 2022, Volume 17, 1089-1106.	2.3	1
8	Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 714-734.	5.7	66
9	The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 57, 2002436.	6.7	4
10	Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. <i>Thorax</i> , 2021, 76, 733-736.	5.6	16
11	A Systematic Review and Appraisal of Epidemiological Studies on Household Fuel Use and Its Health Effects Using Demographic and Health Surveys. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1411.	2.6	21
12	Referral criteria to palliative care for patients with respiratory disease: a systematic review. <i>European Respiratory Journal</i> , 2021, 58, 2004307.	6.7	10
13	Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2090-2101.	5.7	27
14	Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles. <i>Annals of Translational Medicine</i> , 2021, 9, 586-586.	1.7	1
15	Plasma Extracellular Vesicle miRNAs Can Identify Lung Cancer, Current Smoking Status, and Stable COPD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5803.	4.1	19
16	Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB™s role in oncogenesis. <i>Human Molecular Genetics</i> , 2021, 30, 2393-2401.	2.9	3
17	Women™s empowerment as a pathway to sustainable and modern energy for all: evidence from the Demographic and Health Surveys. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
18	Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. <i>BMJ Open</i> , 2021, 11, e053446.	1.9	1

#	ARTICLE	IF	CITATIONS
19	E-cigarettes induce toxicity comparable to tobacco cigarettes in airway epithelium from patients with COPD. <i>Toxicology in Vitro</i> , 2021, 75, 105204.	2.4	24
20	Behaviour change: The key to implementing evidence on <sc>COPD</sc> prevention, diagnosis and management. <i>Respirology</i> , 2021, 26, 1021-1023.	2.3	2
21	Validation of the Eighth Edition TNM Lung Cancer Staging System. <i>Journal of Thoracic Oncology</i> , 2020, 15, 649-654.	1.1	25
22	â€ˆOmicâ€™™: The new language in medicine that we all must learn. <i>Respirology</i> , 2020, 25, 137-138.	2.3	1
23	Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. <i>Nature Communications</i> , 2020, 11, 5886.	12.8	194
24	Concise guidance for <sc>COPD</sc>. <i>Respirology</i> , 2020, 25, 1129-1132.	2.3	5
25	Use of eHealth in the management of pulmonary arterial hypertension: review of the literature. <i>BMJ Health and Care Informatics</i> , 2020, 27, e100176.	3.0	6
26	The role of the microbiome and the NLRP3 inflammasome in the gut and lung. <i>Journal of Leukocyte Biology</i> , 2020, 108, 925-935.	3.3	58
27	Management of acute COPD exacerbations in Australia: do we follow the guidelines?. <i>ERJ Open Research</i> , 2020, 6, 00270-2019.	2.6	13
28	Diagnosis and treatment of lung disease associated with alpha oneâ€ˆantitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*. <i>Respirology</i> , 2020, 25, 321-335.	2.3	12
29	Protocol and Rationale for the International Lung Screening Trial. <i>Annals of the American Thoracic Society</i> , 2020, 17, 503-512.	3.2	56
30	Effects of Different Telemonitoring Strategies on Chronic Heart Failure Care: Systematic Review and Subgroup Meta-Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e20032.	4.3	29
31	Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 554.	2.6	43
32	Diagnosis and treatment of early lung cancer. <i>Australian Journal of General Practice</i> , 2020, 49, 508-512.	0.8	4
33	Cost of screening for lung cancer in Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1392-1399.	0.8	8
34	The cytotoxic, inflammatory and oxidative potential of coconut oil-substituted diesel emissions on bronchial epithelial cells at an air-liquid interface. <i>Environmental Science and Pollution Research</i> , 2019, 26, 27783-27791.	5.3	14
35	Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. <i>Journal of Thoracic Disease</i> , 2019, 11, S2200-S2209.	1.4	9
36	Euler-Lagrange Prediction of Diesel-Exhaust Polydisperse Particle Transport and Deposition in Lung: Anatomy and Turbulence Effects. <i>Scientific Reports</i> , 2019, 9, 12423.	3.3	32

#	ARTICLE	IF	CITATIONS
37	Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ANZ Journal of Surgery, 2019, 89, E406-E407.	0.7	1
38	Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis, 2019, 40, 724-734.	2.8	24
39	CRISPR-Cas9 technology: A new direction for personalized medicine in respiratory disease?. Respiriology, 2019, 24, 614-615.	2.3	2
40	Evaluation of an innovative mobile health programme for the self-management of chronic obstructive pulmonary disease (MH-COPD): protocol of a randomised controlled trial. BMJ Open, 2019, 9, e025381.	1.9	12
41	Long-Term Azithromycin Reduces <i>Haemophilus influenzae</i> and Increases Antibiotic Resistance in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 309-317.	5.6	121
42	Primary human bronchial epithelial cell responses to diesel and biodiesel emissions at an air-liquid interface. Toxicology in Vitro, 2019, 57, 67-75.	2.4	12
43	A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 51-60.e11.	2.9	50
44	Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD. Breathe, 2019, 15, 306-316.	1.3	11
45	Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research, 2019, 5, 00056-2019.	2.6	27
46	EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 2019, 7, S326-S326.	1.7	0
47	Cognitive behavioural therapy (CBT) for patients with chronic lung disease and psychological comorbidities undergoing pulmonary rehabilitation. Journal of Thoracic Disease, 2019, 11, S2238-S2253.	1.4	13
48	Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. Journal of Thoracic Disease, 2019, 11, S2230-S2237.	1.4	59
49	Pre-hospital and emergency department pathways of care for exacerbations of chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2019, 11, S2221-S2229.	1.4	7
50	Potential clinical utility of multiple target quantitative polymerase chain reaction (qPCR) array to detect microbial pathogens in patients with chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2019, 11, S2254-S2265.	1.4	4
51	COPD and the gut-lung axis: the therapeutic potential of fibre. Journal of Thoracic Disease, 2019, 11, S2173-S2180.	1.4	64
52	Diagnostic approach to chronic dyspnoea in adults. Journal of Thoracic Disease, 2019, 11, S2117-S2128.	1.4	16
53	Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of Thoracic Disease, 2019, 11, S2155-S2172.	1.4	76
54	Extracellular vesicles in chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2019, 11, S2141-S2154.	1.4	36

#	ARTICLE	IF	CITATIONS
55	Personalised multidisciplinary management for patients with chronic obstructive pulmonary disease (COPD). <i>Journal of Thoracic Disease</i> , 2019, 11, S2115-S2116.	1.4	0
56	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. <i>Respirology</i> , 2019, 24, 37-47.	2.3	136
57	The effect of diesel emission exposure on primary human bronchial epithelial cells from a COPD cohort: N-acetylcysteine as a potential protective intervention. <i>Environmental Research</i> , 2019, 170, 194-202.	7.5	14
58	Interstitial lung abnormalities in the Queensland Lung Cancer Screening Study: prevalence and progression over 2 years of surveillance. <i>Internal Medicine Journal</i> , 2019, 49, 843-849.	0.8	12
59	The contribution of respiratory microbiome analysis to a treatable traits model of care. <i>Respirology</i> , 2019, 24, 19-28.	2.3	8
60	Clinical management practices of life-threatening asthma: an audit of practices in intensive care. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2019, 21, 53-62.	0.1	2
61	Working while unwell: Workplace impairment in people with severe asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 650-662.	2.9	57
62	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	28.9	1,670
63	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018, 173, 291-304.e6.	28.9	1,718
64	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018, 173, 386-399.e12.	28.9	228
65	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	28.9	272
66	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	28.9	1,417
67	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	28.9	2,111
68	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	28.9	620
69	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4.	6.4	333
70	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	6.4	407
71	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
72	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018, 23, 297-312.e12.	6.4	205

#	ARTICLE	IF	CITATIONS
73	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
74	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
75	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
76	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
77	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
78	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
79	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	6.4	204
80	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	6.4	177
81	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 2018, 2018, CD006847.	2.8	44
82	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
83	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
84	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
85	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
86	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
87	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
88	Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. Journal of Allergy and Clinical Immunology, 2018, 141, 94-103.e15.	2.9	233
89	RE: Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2018, 110, 432-432.	6.3	7
90	Diagnosis of the cause of chronic dyspnoea in primary and tertiary care: characterizing diagnostic confidence. Journal of Thoracic Disease, 2018, 10, 3745-3756.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Editorial on PanCan study. Translational Lung Cancer Research, 2018, 7, S57-S59.	2.8	0
92	Subtype variation and actionability of telomere length abnormality in lung cancer. Translational Lung Cancer Research, 2018, 7, S251-S253.	2.8	3
93	Polydisperse Microparticle Transport and Deposition to the Terminal Bronchioles in a Heterogeneous Vasculature Tree. Scientific Reports, 2018, 8, 16387.	3.3	29
94	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
95	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports, 2018, 25, 1304-1317.e5.	6.4	329
96	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
97	How do new molecular tools apply to my clinical practice?. Respiriology, 2018, 23, 991-992.	2.3	0
98	Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics. Cancer Research, 2018, 78, 3287-3287.	0.9	49
99	Oxidative potential of gas phase combustion emissions - An underestimated and potentially harmful component of air pollution from combustion processes. Atmospheric Environment, 2017, 158, 227-235.	4.1	26
100	The effect of different radiological models on diagnostic accuracy and lung cancer screening performance. Thorax, 2017, 72, 1147-1150.	5.6	14
101	Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma. The Cochrane Library, 2017, , .	2.8	1
102	Pulmonary aerosol transport and deposition analysis in upper 17 generations of the human respiratory tract. Journal of Aerosol Science, 2017, 108, 29-43.	3.8	89
103	Low tumour cell content in a lung tumour bank: implications for molecular characterisation. Pathology, 2017, 49, 611-617.	0.6	3
104	Ultrafine particle transport and deposition in a large scale 17-generation lung model. Journal of Biomechanics, 2017, 64, 16-25.	2.1	34
105	Is Digital Tomosynthesis on Par With Computed Tomography for the Detection and Measurement of Pulmonary Nodules?. Journal of Thoracic Imaging, 2017, 32, W67-W68.	1.5	1
106	Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 659-668.	13.7	489
107	COPDâ€ Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Medical Journal of Australia, 2017, 207, 436-442.	1.7	129
108	Genomics of lung cancer. Journal of Thoracic Disease, 2017, 9, E155-E157.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
110	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane Library, 2016, 2016, CD002991.	2.8	281
111	Utility of thrombophilia testing in patients with venous thrombo-embolism. Journal of Thoracic Disease, 2016, 8, 3697-3703.	1.4	11
112	A survey of lung cancer in rural and remote Aboriginal and Torres Strait Islander communities in Queensland: health views that impact on early diagnosis and treatment. Internal Medicine Journal, 2016, 46, 171-176.	0.8	10
113	Blood cytotoxic/inflammatory mediators in non- ϵ eosinophilic asthma. Clinical and Experimental Allergy, 2016, 46, 60-70.	2.9	13
114	Acute exacerbation of COPD. Respiriology, 2016, 21, 1152-1165.	2.3	213
115	Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Internal Medicine Journal, 2016, 46, 1054-1062.	0.8	68
116	Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clinical and Experimental Allergy, 2016, 46, 1407-1415.	2.9	29
117	Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulmonary Medicine, 2016, 16, 67.	2.0	55
118	Airway dysbiosis: <i>Haemophilus influenzae</i> and <i>Tropheryma</i> in poorly controlled asthma. European Respiratory Journal, 2016, 47, 792-800.	6.7	159
119	Reduced Antiviral Interferon Production in Poorly Controlled Asthma Is Associated With Neutrophilic Inflammation and High-Dose Inhaled Corticosteroids. Chest, 2016, 149, 704-713.	0.8	64
120	Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine, 2016, 10, 339-350.	2.5	7
121	Brief Tailored Smoking Cessation Counseling in a Lung Cancer Screening Population is Feasible: A Pilot Randomized Controlled Trial: Table 1.. Nicotine and Tobacco Research, 2016, 18, 1665-1669.	2.6	35
122	Screen-detected subsolid pulmonary nodules: long-term follow-up and application of the PanCan lung cancer risk prediction model. British Journal of Radiology, 2016, 89, 20160016.	2.2	18
123	How microRNA's orchestrate the lung's biological responses. Respiriology, 2015, 20, 1149-1150.	2.3	3
124	Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1 β . Respiratory Research, 2015, 16, 5.	3.6	66
125	Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in Resected Stage 1 Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 673-681.	1.1	32
126	Lung cancer screening feasibility in Australia. European Respiratory Journal, 2015, 45, 1734-1737.	6.7	24

#	ARTICLE	IF	CITATIONS
127	Year in review 2014: Chronic obstructive pulmonary disease, asthma and airway biology. <i>Respirology</i> , 2015, 20, 510-518.	2.3	0
128	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. <i>Oncotarget</i> , 2015, 6, 394-408.	1.8	27
129	Altered sputum granzyme B and granzyme B/proteinase inhibitor-9 in patients with non-eosinophilic asthma. <i>Respirology</i> , 2014, 19, 280-287.	2.3	9
130	MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression. <i>BMC Genomics</i> , 2014, 15, 88.	2.8	76
131	Electromagnetic navigation bronchoscopy for the diagnosis of <i>Aspergillus</i> infection. <i>Respirology Case Reports</i> , 2014, 2, 30-32.	0.6	2
132	Year in review 2013: Chronic obstructive pulmonary disease, asthma and airway biology. <i>Respirology</i> , 2014, 19, 438-447.	2.3	4
133	A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. <i>Respirology</i> , 2014, 19, 755-762.	2.3	33
134	Full blood count parameters for the detection of asthma inflammatory phenotypes. <i>Clinical and Experimental Allergy</i> , 2014, 44, 1137-1145.	2.9	178
135	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014, 511, 543-550.	27.8	4,572
136	Levels of anti-cytokine antibodies may be elevated in patients with pulmonary disease associated with non-tuberculous mycobacteria. <i>Cytokine</i> , 2014, 66, 160-163.	3.2	18
137	Coronary Artery Calcification on Computed Tomography Correlates With Mortality in Chronic Obstructive Pulmonary Disease. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 753-759.	0.9	19
138	Anxiety and depression-Important psychological comorbidities of COPD. <i>Journal of Thoracic Disease</i> , 2014, 6, 1615-31.	1.4	144
139	Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. <i>Journal of Thoracic Disease</i> , 2014, 6, 1586-96.	1.4	42
140	Biomarkers of progression of chronic obstructive pulmonary disease (COPD). <i>Journal of Thoracic Disease</i> , 2014, 6, 1532-47.	1.4	111
141	Year in review 2012: Asthma and chronic obstructive pulmonary disease. <i>Respirology</i> , 2013, 18, 565-572.	2.3	2
142	Air pollution and lung health: An epilogue. <i>Respirology</i> , 2013, 18, 3-4.	2.3	8
143	Impaired macrophage phagocytosis in non-eosinophilic asthma. <i>Clinical and Experimental Allergy</i> , 2013, 43, 29-35.	2.9	96
144	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521.	2.8	67

#	ARTICLE	IF	CITATIONS
145	Mediastinal Abscess After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2013, 20, 338-341.	1.4	21
146	Peripheral compartment innate immune response to <i>Haemophilus influenzae</i> and <i>Streptococcus pneumoniae</i> in chronic obstructive pulmonary disease patients. <i>Innate Immunity</i> , 2013, 19, 428-437.	2.4	4
147	Queensland Lung Cancer Screening Study: rationale, design and methods. <i>Internal Medicine Journal</i> , 2013, 43, 174-182.	0.8	17
148	Personalizing and targeting therapy for COPD – the role of molecular and clinical biomarkers. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 593-605.	2.5	12
149	Glycopyrronium bromide for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, . .	2.8	1
150	Inhaled corticosteroids for subacute and chronic cough in adults. <i>The Cochrane Library</i> , 2013, 2013, CD009305.	2.8	20
151	Digital tomosynthesis for the detection and management of pulmonary nodules. <i>Lung Cancer Management</i> , 2013, 2, 5-7.	1.5	0
152	Phenotypes and Karyotypes of Human Malignant Mesothelioma Cell Lines. <i>PLoS ONE</i> , 2013, 8, e58132.	2.5	23
153	Genetic susceptibility to lung cancer and co-morbidities. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S454-62.	1.4	49
154	Screening for lung cancer with low-dose computed tomography: a review of current status. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S524-39.	1.4	41
155	An emerging place for lung cancer genomics in 2013. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S491-7.	1.4	22
156	Personalized medicine for lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 83-86.	1.5	2
157	Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. <i>BMC Cancer</i> , 2012, 12, 428.	2.6	46
158	Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). <i>BMC Pulmonary Medicine</i> , 2012, 12, 25.	2.0	7
159	The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. <i>Respirology</i> , 2012, 17, 247-260.	2.3	23
160	Respiratory health effects of diesel particulate matter. <i>Respirology</i> , 2012, 17, 201-212.	2.3	247
161	Year in review 2011: Asthma, chronic obstructive pulmonary disease and airway biology. <i>Respirology</i> , 2012, 17, 563-572.	2.3	6
162	Genomics and the respiratory effects of air pollution exposure. <i>Respirology</i> , 2012, 17, 590-600.	2.3	70

#	ARTICLE	IF	CITATIONS
163	Array-Comparative Genomic Hybridization Reveals Loss of SOCS6 Is Associated with Poor Prognosis in Primary Lung Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e30398.	2.5	28
164	MS4A1 Dysregulation in Asbestos-Related Lung Squamous Cell Carcinoma Is Due to CD20 Stromal Lymphocyte Expression. PLoS ONE, 2012, 7, e34943.	2.5	27
165	Whole genome sequencing for lung cancer. Journal of Thoracic Disease, 2012, 4, 155-63.	1.4	28
166	Electromagnetic navigation bronchoscopy: A descriptive analysis. Journal of Thoracic Disease, 2012, 4, 173-85.	1.4	75
167	Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology, 2011, 7, 737-752.	2.4	61
168	Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. European Respiratory Journal, 2011, 38, 903-910.	6.7	28
169	Genes and Gene Ontologies Common to Airflow Obstruction and Emphysema in the Lungs of Patients with COPD. PLoS ONE, 2011, 6, e17442.	2.5	26
170	Genomic medicine in non-small cell lung cancer: Paving the path to personalized care. Respirology, 2011, 16, 257-263.	2.3	18
171	Mesothelial markers in high-grade breast carcinoma. Histopathology, 2011, 59, 957-964.	2.9	18
172	Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 439-456.	3.4	77
173	<i>ADAM28</i> : A potential oncogene involved in asbestos-related lung adenocarcinomas. Genes Chromosomes and Cancer, 2010, 49, 688-698.	2.8	24
174	Year in Review 2009: Asthma, COPD and airway biology. Respirology, 2010, 15, 365-376.	2.3	3
175	Exploratory study of the "weekend effect"™ for acute medical admissions to public hospitals in Queensland, Australia. Internal Medicine Journal, 2010, 40, 777-783.	0.8	59
176	MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12560.	2.5	100
177	Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. European Respiratory Journal, 2010, 35, 152-159.	6.7	44
178	EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321.	0.2	2
179	Genetics of allergic disease. Journal of Allergy and Clinical Immunology, 2010, 125, S81-S94.	2.9	187
180	Variability in the rate of prescription and cost of domiciliary oxygen therapy in Australia. Medical Journal of Australia, 2009, 191, 549-553.	1.7	18

#	ARTICLE	IF	CITATIONS
181	Epigenomic targets for the treatment of respiratory disease. Expert Opinion on Therapeutic Targets, 2009, 13, 625-640.	3.4	30
182	Mortality in adult intensive care patients with severe systemic inflammatory response syndromes is strongly associated with the hypo-immune TNF α 238A polymorphism. Immunogenetics, 2009, 61, 657-662.	2.4	22
183	Deconstructing COPD using genomic tools. Respiriology, 2009, 14, 313-317.	2.3	9
184	Respirology year in review 2008: Basic science. Respiriology, 2009, 14, 318-326.	2.3	0
185	Expression profiling identifies genes involved in emphysema severity. Respiratory Research, 2009, 10, 81.	3.6	35
186	Genomics of Lung Cancer. , 2009, , 856-868.		0
187	Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer, 2008, 60, 14-21.	2.0	125
188	Interpatient variability in rates of asthma progression: Can genetics provide an answer?. Journal of Allergy and Clinical Immunology, 2008, 121, 573-579.	2.9	16
189	Rationale and design of the PRSM study: Pulmonary rehabilitation or self management for chronic obstructive pulmonary disease (COPD), what is the best approach?. Contemporary Clinical Trials, 2008, 29, 796-800.	1.8	12
190	Genetic susceptibility to the respiratory effects of air pollution. Thorax, 2008, 63, 555-563.	5.6	145
191	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, , CD002991.		103
192	Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. European Respiratory Journal, 2007, 30, 21-26.	6.7	20
193	Genetic association studies of interleukin-13 receptor α 1 subunit gene polymorphisms in asthma and atopy. European Respiratory Journal, 2007, 30, 40-47.	6.7	16
194	Arg389Gly β 1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 2007, 17, 941-949.	1.5	78
195	Gene-environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 75-82.	2.3	46
196	β 2-ADRENOCEPTOR POLYMORPHISMS AND OBSTRUCTIVE AIRWAY DISEASES: IMPORTANT ISSUES OF STUDY DESIGN. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 1029-1036.	1.9	9
197	Asthma: advancing gene-environment studies. Clinical and Experimental Allergy, 2007, 37, 1264-1266.	2.9	7
198	(-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through β 2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with G_s coupling but not with G_i coupling. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 375, 11-28.	3.0	44

#	ARTICLE	IF	CITATIONS
199	Association of asthma with a functional promoter polymorphism in the IL16 gene. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 86-91.	2.9	34
200	The role of Toll-like receptors and related receptors of the innate immune system in asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2006, 6, 23-28.	2.3	75
201	Epigenetics of lung cancer. <i>Respirology</i> , 2006, 11, 355-365.	2.3	52
202	CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. <i>Carcinogenesis</i> , 2006, 27, 525-532.	2.8	66
203	Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 15-21.	1.5	75
204	Mucociliary clearance in patients with chronic asthma: Effects of beta2 agonists. <i>Respirology</i> , 2005, 10, 426-435.	2.3	25
205	Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. <i>Cancer Causes and Control</i> , 2005, 16, 579-585.	1.8	31
206	Association of Tumor Necrosis Factor- β Polymorphisms and Ozone-induced Change in Lung Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 171-176.	5.6	80
207	Effectiveness of Hospital-Based Smoking Cessation. <i>Chest</i> , 2005, 128, 216-223.	0.8	22
208	Cochrane systematic reviews of treatments for lung cancer. <i>Respiratory Medicine</i> , 2005, 99, 1071-1078.	2.9	7
209	β -Adrenergic receptor polymorphism and asthma: True or false?. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 960-962.	2.9	14
210	Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. <i>Internal Medicine Journal</i> , 2004, 34, 126-129.	0.8	46
211	Toll-like receptor polymorphisms and allergic disease: interpreting the evidence from genetic studies. <i>Clinical and Experimental Allergy</i> , 2004, 34, 163-166.	2.9	21
212	Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. <i>Genes and Immunity</i> , 2004, 5, 41-45.	4.1	133
213	Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 889-895.	2.9	66
214	Erratum to "TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis" [ATH 170 (2003) 187-190]. <i>Atherosclerosis</i> , 2004, 173, 155.	0.8	0
215	(-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the β ₁ -adrenoceptor. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 367, 10-21.	3.0	49
216	Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. <i>Genes and Immunity</i> , 2003, 4, 269-274.	4.1	67

#	ARTICLE	IF	CITATIONS
217	TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. <i>Atherosclerosis</i> , 2003, 170, 187-190.	0.8	101
218	Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. <i>Biochemical Society Transactions</i> , 2003, 31, 652-653.	3.4	90
219	Conservation of the cardiostimulant effects of (α^1)-norepinephrine across Ser49Gly and Gly389Arg beta1-adrenergic receptor polymorphisms in human right atrium in vitro. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1275-1282.	2.8	51
220	Trepopnoea due to positional narrowing of the left main bronchus. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 838-839.	0.5	0
221	Antibiotics in Chronic Obstructive Pulmonary Disease, Bronchiectasis and Cystic Fibrosis. , 0, , 389-413.		2
222	Gefitinib for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	2.8	3
223	The current and future roles of genomics. , 0, , 79-94.		0